Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05513014 · ClinicalTrials.gov registry record
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,518
- Enrollment target
NCT05513014 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,518 participants.
The verdict
NCT05513014 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,518 participants
- Enrollment target
Study Summary
The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,518 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2021-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05513014
The ClinicalTrials.gov registry entry for NCT05513014 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05513014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05513014 about?
NCT05513014 is a clinical study titled "Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis". The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).
What is the current status of trial NCT05513014?
This trial is currently completed. The enrollment target is 1,518 participants. The study started on 2021-03-21. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT05513014?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT05513014?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.